PIK3CA and prostate carcinoma: A variety of PI3K/AKT inhibitors are currently under investigation in prostate cancer in combination with other therapies such as ARSIs, docetaxel, bicalutamide, and hydroxychloroquine (NCT06190899, NCT03218826, NCT05348577, NCT01480154, NCT04586270, NCT01251861).